51
|
Canard C, Diaz E, Gusdorf L, Loget J, Durlach A, Graesslin O, Cadiot G, Viguier M. [Isolated Crohn's disease of the vulva with rapid clinical response to infliximab and azathioprine]. Ann Dermatol Venereol 2020; 147:569-571. [PMID: 32505375 DOI: 10.1016/j.annder.2020.04.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 03/15/2020] [Accepted: 04/22/2020] [Indexed: 11/15/2022]
|
52
|
Villani AP, Amatore F, Tauber M, Guillot B, Viguier M, Beylot-Barry M, Jullien D. Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2020; 34:e747-e748. [PMID: 32396980 DOI: 10.1111/jdv.16601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 04/30/2020] [Indexed: 11/28/2022]
|
53
|
Condamina M, Diaz E, Jamart C, Loget J, Durlach A, Salmon JH, Cadiot G, Viguier M. Severe Attack of Henoch-Schönlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn's Disease. J Crohns Colitis 2020; 14:538-542. [PMID: 31589303 DOI: 10.1093/ecco-jcc/jjz164] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Tumour necrosis factor-α [TNF-α] inhibitors have revolutionised the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn's disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurological involvement, requiring definitive TNF blocker withdrawal.
Collapse
|
54
|
Clapé A, Muller C, Plée J, Viguier M, Vanhaecke C, Bernard P. Feasibility and healthcare costs of superpotent topical corticosteroid therapy in bullous pemphigoid: a prospective, observational study in an academic centre in France. Br J Dermatol 2020; 183:775-776. [PMID: 32320476 DOI: 10.1111/bjd.19151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
55
|
Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, D'Incan M, Conrad C, Brenaut E, Girard C, Richard M, Bachelez H, Viguier M. Efficacy and safety of
TNF
blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol 2020; 34:2330-2338. [DOI: 10.1111/jdv.16265] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/21/2020] [Indexed: 12/12/2022]
|
56
|
Chelli C, Loget J, Vanhaecke C, Durlach A, Gagneux-Lemoussu L, Soriano C, Viguier M. Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis. Acta Derm Venereol 2020; 100:adv00077. [PMID: 32115666 PMCID: PMC9128929 DOI: 10.2340/00015555-3435] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
57
|
Amatore F, Villani AP, Tauber M, Guillot B, Viguier M. Erratum à « Recommandations françaises sur l’utilisation des traitements systémiques chez les patients adultes atteints de psoriasis modéré à sévère » [Ann. Dermatol. Venereol. 146 (6–7) (2019) 429–439]. Ann Dermatol Venereol 2020; 147:114-115. [DOI: 10.1016/j.annder.2019.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
58
|
Sigg N, Delaunay J, Livideanu CB, Aubin F, Bachelez H, Charles J, Dupuy A, Girard C, Goujon-Henry C, D’Incan M, Jullien D, Ly S, Maillard H, Misery L, Montaudié H, Parier J, Perrussel M, Richard MA, Seneschal J, Staumont-Salle D, Viguier M, Bénéton N. Eruptions cutanées dysimmunitaires et inflammatoires au cours d’un traitement par anti IL-17 dans le psoriasis: 47 cas. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
59
|
Diaz E, Vanhaecke C, Sanchez J, Durlach A, Gusdorf L, Viguier M. Angiomatose dermique diffuse ulcérée multifocale. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
60
|
Maincent O, Husson B, Kieffer J, Durlach A, Cribier B, Viguier M. Prurigo pigmentosa chez une femme enceinte. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
61
|
Clapé A, Muller C, Antonicelli F, Vanhaecke C, Viguier M, Plée J, Bernard P. Enquête de pratique de la prise en charge de la pemphigoïde bulleuse : place et coût de la dermocorticothérapie forte. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
62
|
Assan F, Giboin C, Viguier M, Beylot-Barry M, Dupuy A, Bénéton N, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Bachelez H, Tubach F, Chosidow O, Sbidian E. Impact de l’obésité sur l’efficacité et la tolérance du premier biomédicament : analyse à partir de la cohorte nationale Psobioteq. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
63
|
Chelli C, Loget J, Vanhaecke C, Durlach A, Gagneux Lemoussu L, Soriano C, Viguier M. Vascularite cutanée sévère avec atteinte digestive développée sous sécukinumab. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
64
|
Prouteau C, Dinulescu M, Oger E, Pruvost-Balland C, Buche S, Cogrel O, Delage M, Maruani A, Nicol I, Sbidian E, Villani A, Viguier M, Chastagner M, Grodner C, Kaoutar J, Laurent C, Leducq S, Dupuy A, Droitcourt C. Concordance de scores d’activité évalués sur photographies dans l’hidradénite suppurée. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
65
|
Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol 2019; 34:293-300. [PMID: 31419355 DOI: 10.1111/jdv.15878] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Accepted: 07/17/2019] [Indexed: 01/10/2023]
Abstract
BACKGROUND Numerous inclusion and exclusion criteria are involved in phase III moderate to severe psoriasis trials investigating the safety and efficacy of biologics. This questions the generalization of results. METHODS In this cohort study, we applied inclusion/exclusion criteria for phase III trials from original protocols (adalimumab - REVEAL, ustekinumab - PHOENIX, brodalumab - AMAGINE, secukinumab FIXTURE) to all patients enrolled in the PsoBioTeq prospective registry who received a biological agent for the first time between July 2012 and November 2017. We then compared the efficacy, drug survival and occurrence of adverse events between patients who satisfied/did not satisfy the eligibility criteria for these phase III trials. RESULTS A total of 1267 patients were enrolled, of whom 993 (78.4%) were not eligible for at least one RCT (randomized controlled trial) and 251 (19.1%) did not meet the PASI/PGA severity requirements. Apart from disease severity, the most frequent criteria resulting in exclusion were as follows: non-plaque psoriasis (12.6%), significant cardiac disease (8.4%), significant liver disease (7.3%), elevated liver enzymes (4.9-9.6%) and personal history of diabetes (9.2%). There was no difference in drug survival between the two groups. The incidence ratio of adverse events was significantly lower in eligible versus non-eligible patients [0.78 (95% CI 0.62-0.97) (P = 0.03)]. CONCLUSION The majority of patients treated with biologics in the PsoBioTeq real-life registry would not have been eligible for phase III moderate to severe psoriasis trials. Patients not eligible for psoriasis phase III clinical trials have a higher incidence of adverse events.
Collapse
|
66
|
Stien S, Loget J, Soibinet P, Durlach A, Fleury C, Viguier M. [Ovarian cancer revealed by mammary skin metastases and cutaneous lymphangitis]. Ann Dermatol Venereol 2019; 146:663-665. [PMID: 31522828 DOI: 10.1016/j.annder.2019.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Revised: 03/15/2019] [Accepted: 08/05/2019] [Indexed: 11/26/2022]
|
67
|
Nesmond S, Muller C, Le Naour R, Viguier M, Bernard P, Antonicelli F, Le Jan S. Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes/Macrophages and Mast Cells From Patients With Bullous Pemphigoid. Front Immunol 2019; 10:2107. [PMID: 31572359 PMCID: PMC6749098 DOI: 10.3389/fimmu.2019.02107] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 08/21/2019] [Indexed: 01/08/2023] Open
Abstract
Inflammation is largely implicated in bullous pemphigoid (BP), the most frequent skin auto-immune blistering disease. IL-17, essentially IL-17A/F, has been involved in blister formation through regulation of protease production, and its specific serum profile within BP was related to disease outcome. However, relationships between IL-17 family ligands and receptors are quite complex with six different IL-17 isoforms, and five different receptors. We here aimed at clarifying the contribution of the IL-17 axis in BP by characterizing not only the expression of IL-17 receptor (IL-17R) members within immune cells isolated from BP patients (PMNs, n = 9; T-lymphocytes, n = 10; and monocytes, n = 10) but also the expression of IL-17 isoforms in sera (n = 83), and blister fluid (n = 31) of BP patients. We showed that at diagnosis, IL-17RA and IL-17RC expression were significantly increased in monocytes isolated from BP patients as compared to those from control subjects (p = 0.006 and p = 0.016, respectively). Notably, both IL-17RA and IL-17RC mRNA expression remained elevated in BP monocytes at time of relapse. We further demonstrated a significant increase of all IL-17 isoforms tested in BP blister fluid compared with BP serum (IL-17A, p < 0.0001; IL-17A/F, p < 0.0001; IL-17B, p = 0.0023; IL-17C, p = 0.0022; IL-17E, p < 0.0001). Among all, IL-17B was the only cytokine for which a significant decreased concentration within blister fluid was observed in BP patients with severe disease compared to patients with moderate disease (p = 0.012). We further evidenced a significant negative correlation between IL-17B levels and blister/erosion BPDAI subscore (r = −0.52, p = 0.003). We finally identified mast cells as a potential target of IL-17B in lesional skin of BP patients. In conclusion, we showed here that IL-17RA and IL-17RC expression in monocyte was associated with disease activity and evidenced in situ a negative correlation between BP disease activity and IL-17B, whose effects could be mediated by IL-17RB expressed by mast cell in BP lesional skin.
Collapse
|
68
|
Prouteau C, Dinulescu M, Oger E, Pruvost-Balland C, Buche S, Cogrel O, Delage M, Maruani A, Nicol I, Sbidian E, Villani AP, Viguier M, Chastagner M, Grodner C, Kaoutar J, Laurent C, Leducq S, Dupuy A, Droitcourt C. Concordance of severity scores for photographic assessment of hidradenitis suppurativa. Br J Dermatol 2019; 182:515-516. [PMID: 31494929 DOI: 10.1111/bjd.18480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
69
|
Maho-Vaillant M, Pérals C, Golinski M, Hébert V, Riou G, Boyer O, Viguier M, Calbo S, Fazilleau N, Joly P. 018 Evolution of autoreactive B and T cells in pemphigus patients with Rituximab or corticosteroida regimen treatment. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
70
|
Sbidian E, Madrange M, Viguier M, Salmona M, Duchatelet S, Hovnanian A, Smahi A, Le Goff J, Bachelez H. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol 2019; 181:1304-1306. [PMID: 31150103 PMCID: PMC7161746 DOI: 10.1111/bjd.18203] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
71
|
Jachiet M, Nosbaum A, Staumont-Sallé D, Seneschal J, Viguier M, Soria A, Barbaud A, Carriou AC, Chuffart-Delplanque M, Darrigade AS, Fite C, de Masson A, Bagot M, Chevret S, Bouaziz JD. Low cardiovascular risk and poor quality of life associated with tobacco use and skin infections in adult atopic dermatitis: result of a French multicenter study. J Eur Acad Dermatol Venereol 2019; 33:e451-e453. [PMID: 31273834 DOI: 10.1111/jdv.15774] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
72
|
Amatore F, Villani AP, Tauber M, Guillot B, Viguier M. Recommandations françaises sur l’utilisation des traitements systémiques chez les patients adultes atteints de psoriasis modéré à sévère. Ann Dermatol Venereol 2019; 146:429-439. [DOI: 10.1016/j.annder.2019.03.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
73
|
Viguier M, Aubin F, Bachelez H, Beylot-Barry M, Richard MA. Éditorial. Ann Dermatol Venereol 2019; 146:423-425. [DOI: 10.1016/j.annder.2019.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
74
|
Viguier M. Biosimilaires des anti-TNF dans le traitement du psoriasis. Ann Dermatol Venereol 2019; 146:492-496. [DOI: 10.1016/j.annder.2019.04.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
75
|
Droitcourt C, Barbarot S, Maruani A, Darrieux L, Misery L, Brenaut E, Adamski H, Chabbert C, Vermersch A, Weiborn M, Seneschal J, Taïeb A, Plantin P, Maillard H, Phan A, Skowron F, Viguier M, Staumont-Salle D, Nosbaum A, Soria A, Barbaud A, Oger E, Dupuy A. A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial. Trials 2019; 20:184. [PMID: 30909923 PMCID: PMC6434814 DOI: 10.1186/s13063-019-3276-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 03/01/2019] [Indexed: 12/05/2022] Open
Abstract
Background Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates. Methods This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter. Discussion This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health. Trial registration ClinicalTrials.gov Identifier: NCT02537509, first received: 1 September 2015. Electronic supplementary material The online version of this article (10.1186/s13063-019-3276-9) contains supplementary material, which is available to authorized users.
Collapse
|